ACCESSWIRE

BCLI SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / November 20, 2023 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or "the Company") (NASDAQ:BCLI) and certain of its officers.

Class Definition:

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Brainstorm Cell securities between August 15, 2022 and September 27, 2023, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/bcli.

Case Details:

The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Brainstorm Cell downplayed the severity of the U.S. Food and Drug Administration's ("FDA") refusal to file letter; (2) Brainstorm Cell continued to conceal the risks associated with the submission of the biologics license application ("BLA"); and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/bcli or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Brainstorm Cell you have until January 2, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/800133/bcli-shareholder-alert-bronstein-gewirtz-grossman-llc-announces-that-brainstorm-cell-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit

NOTE: This content is not written by or endorsed by "WTTV", its advertisers, or Nexstar Media Inc.

For inquiries or corrections to Press Releases, please reach out to Accesswire.